vTv Therapeutics Inc. — 2021 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2021. This annual filing reports full-year results, not standalone fourth-quarter results. vTv is a clinical-stage biopharmaceutical company with no approved products and no product-sales revenue; collaboration and licensing arrangements are its principal revenue source.
Key financial metrics
| Metric | 2021 | 2020 |
|---|---|---|
| Revenue | $4.0 million | $6.4 million |
| Research and development expense | $13.3 million | $11.0 million |
| General and administrative expense | $12.3 million | $7.3 million |
| Operating loss | $(21.7) million | $(11.9) million |
| Net loss attributable to vTv Therapeutics Inc. | $(13.0) million | $(8.5) million |
| Net cash used in operating activities | $(19.3) million | $(18.0) million |
| Cash and cash equivalents at year-end | $13.4 million | $5.7 million |
2021 revenue was down about 38% year over year, primarily reflecting the absence of the prior-year Anteris license revenue. 2021 revenue included milestone revenue from Reneo and Newsoara and a revenue adjustment related to the Huadong agreement. Operating expenses increased, including restructuring-related costs and TTP399 and HPP737 development spending. Other income of $4.1 million—principally an unrealized gain on the Reneo investment and a fair-value gain on related-party warrants—partly offset the operating loss.
Financing activities provided $27.0 million in 2021, chiefly from equity sales; year-end cash increased by $7.7 million. The company reported $9.2 million of long-term investments, $0.3 million of current notes payable, and $0.7 million of operating lease liabilities. Its former venture loan was repaid and terminated in December 2020. The company disclosed substantial doubt about its ability to continue as a going concern. Management’s plan relied on cash and available equity-sale facilities, and it expected to fund operations into the fourth quarter of 2022; access depended on stock price and trading volume and was not assured.
Business developments, outlook, and risks
- TTP399: The lead program is an oral, liver-selective glucokinase activator for type 1 diabetes. The FDA granted Breakthrough Therapy designation in April 2021. In the Phase 2 Simplici-T1 study, the company reported statistically significant HbA1c improvement versus placebo and a 40% reduction in severe and symptomatic hypoglycemia frequency. A 23-person mechanistic study found no increased ketone-related ketoacidosis risk during acute insulin withdrawal. The company planned two pivotal, placebo-controlled trials and expected to begin them in 2022, subject to FDA discussions and funding.
- Strategic shift: The company prioritized TTP399, paused U.S. HPP737 development while considering licensing options, and reduced its workforce by approximately 65% in December 2021. It reported nine employees after the reduction. It was seeking financing, partnering, and licensing transactions for TTP399 and other assets.
- Other programs and partnerships: vTv continued supporting five partnered programs, including GLP-1r, PDE4, PPAR-delta, Nrf2, and azeliragon. It was also seeking a funding partner for a planned TTP273 study in cystic-fibrosis-related diabetes. Partner milestones and royalties remain contingent on development, regulatory and commercial progress.
- Material risks: No product is approved or generating sales; continued operations and planned trials require additional capital. Clinical, regulatory, partner, manufacturing, and intellectual-property outcomes are uncertain. The company relies on third-party manufacturers and does not have multiple supply sources for drug-candidate components. COVID-19 affected some trial timelines, although the company said it did not significantly affect 2021 financial results.
- Capital and governance: The company had $37.3 million remaining under its ATM facility at year-end and $35.9 million of stated remaining capacity under its Lincoln Park purchase agreement, subject to contractual and market limitations. Equity issuance may dilute shareholders. MacAndrews held approximately 66.2% of combined voting power. The company also disclosed a Nasdaq minimum-bid-price deficiency notice and risk of delisting.
- Other notable items: The company recorded $1.6 million of severance and benefits costs associated with the December restructuring. It reported no material legal proceedings. The independent auditor’s report included a going-concern emphasis; the financial statements were prepared on a going-concern basis.
Most important facts for investors to verify
- Current cash runway, subsequent financing, and whether the company can fund the planned TTP399 trials without unacceptable dilution or unfavorable licensing terms.
- Whether the FDA agreed with the pivotal-trial designs and whether the planned 2022 trial starts occurred.
- Full Phase 2 and mechanistic-study data, including the magnitude and durability of clinical benefit and safety findings.
- Progress and economics of any TTP399, HPP737, or other asset partnerships, including milestones actually earned versus potential payments.
- Nasdaq listing compliance, share issuance under the ATM and Lincoln Park facilities, and resulting dilution.
- The composition and realizability of the $4.1 million other-income gain, particularly the Reneo investment valuation and warrant fair-value changes.